Neuroprotective, anti-apoptotic effects of apomorphine

Journal of Anti-Aging Medicine

Volumn 6, Issue 1, 2003, Pages 21-28

  Kyriazis, Marios ^a  

^a British Longevity Society   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOMORPHINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE RECEPTOR; EXCITOTOXIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NITRIC OXIDE; PROTEASOME; UBIQUITIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0038779336     PISSN: 10945458     EISSN: None     Source Type: Journal    
DOI: 10.1089/109454503765361551     Document Type: Review

References (40)

1. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implication of antioxidant treatment. Drugs Aging 2001;18:685-716.
2. Gassen M, Gross A, Youdim M. Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. In: Stern GM, ed. Parkinson's Disease: Advances in Neurology. Philadelphia: Lippincott Williams & Wilkins, 1999, 297-302.
3. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001;18:389-396.
4. Youdim MB, Gassen M, Gross A, et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist: apomorphine. J Neural Transm 2000;58:83-96.
5. O'Sullivan JO, Lees AJ. Use of apomorphine in Parkinson's disease. Hosp Med 1999;60:816-820.
6. Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 2001;33:21-38.
7. Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Dis 1995;10:28-36.
8. Weiser R. Apomorphine nasal powder: pilot study results. Presented at the EFNS Neurology Congress, 2002, Vienna.
9. Ubeda A. Iron reducing and free radical scavenging properties of apomorphine and some related bezylisoquinolines. Free Radic Biol Med 1993;15:159-167.
10. Sam EE, Verbecke N. Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm 1995;10:115-127.
11. Grunblatt E, Mandel S, Maor G, et al. Effects of R- and S-apomorphine on MTTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 2001;77:146-156.
12. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44:S167-S174.
13. Battaglia G, Gesi M, Lenzi P, et al. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann NY Acad Sci 2002;965:254-266.
14. Fornai F, Battaglia G, Gesi M, et al. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 2001;898:27-35.
15. Kuno S, Ohta M, Ohta K, et al. Expression of neurotrophic factors in cultured mouse astroglial cells by apomorphine. Mov Disord 2000;15:23.
16. Levivier M, Przedborski S, Bencsics C, et al. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurones in a rat model of Parkinson's disease. J Neurosci 1995;15:7810-7820.
17. Ohta M, Mizuta I, Ohta K, et al. Apomorphine upregulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000;272:18-22.
18. Guo H, Tang Z, Yu Y, et al. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurones in cultures. Eur J Neurosci 2002;16:1861-1870.
19. Mazzio E, Huber J, Darling S, et al. Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. Neurotoxicology 2001;22:283-288.
20. Zhai S, Yarr M, Doyle SM, et al. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 1996;224:335-343.
21. Zhang Y, Herman B. Ageing and apoptosis. Mech Ageing Dev 2002;123:245-260.
22. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative disease. Expert Opin Investig Drugs 2000;9:747-764.
23. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72-S84.
24. Bharath S, Hsu M, Kaur D, et al. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002;64:1037-1048.
25. Gibson R. Does apoptosis have a role in neurodegeneration? Br Med J 2001;322:1539-1540.
26. Kitamura Y, Kosak T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpiridiniuminduced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998;54:1046-1054.
27. Zuch CL, Nordstroem VK, Briedrick LA, et al. Time course of degenerative alterations in nigral dopaminergic neurons following 6-hydroxydopamine lesion. J Comp Neurol 2000;427:440-454.
28. Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996;308:219-225.
29. Gassen M, Gross A, Youdim BH. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6hydroxydopamine. Mov Dis 1998;13:242-248.
30. Loopuijt LD, Sebens JB. Loss of dopamine receptors in the olfactory bulb of patients with Alzheimer's disease. Brain Res 1990;529:239-244.
31. Lashuel HA, Hartley DM, Balakhaneh D, et al. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002;277:42881-42890.
32. McNaught KS, Bjorklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-1441.
33. Zahran AR, Simmerman N, Carrier S, et al. Erectile dysfunction occurs following substantia nigra lesions in the rat. Int J Impot Res 2001;13:255-260.
34. Allard J, Giuliano F. Central nervous system agents in the treatment of erectile dysfunction: how do they work? Curr Urol Rep 2001;2:488-494.
35. Giuliano F, Allard J. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous systems-acting ED drug. Int J Impot Res 2002;14(Suppl I):S53-S56.
36. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes on monoaminergic receptor. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2) receptor subtypes. J Pharmacol Exp Ther 2002;303:815-822.
37. McCann SM, Licinio J, Wong ML, et al. The nitric oxide hypothesis of aging. Exp Gerontol 1998;33:813-826.
38. Antunes F, Han D, Rettori D, et al. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells. Biochim Biophys Acta 2002;1556:233-238.
39. Melis MR, Stancampiano R, Argiolas A. Prevention by NG-nitri-L-arginine methyl ester of apomorphineand oxytocin-induced penile erection and yawning: site of action in the brain. Pharmacol Biochem Behav 1994;48:779-804.
40. Melis MR, Argiolas A. Reduction of drug-induced yawning and penile erection and of concomitant erections in male rats by the activation of GABAA receptors in the paraventricular nucleus:involvement of nitric oxide. Eur J Neurosci 2002;15:852-860.